{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035865","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.279140+00:00","generated_at":"2026-06-04T13:34:07.404439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Scholar Rock reports FY2023 net loss of $165.8M; cash $280M; SAPPHIRE data expected 4Q 2024","bullets":["Net loss $165.8M ($1.99/share) vs $134.5M ($2.26/share) in FY2022; no revenue vs $33.2M prior year.","R&D spend $121.9M, G&A $49.4M; cash $280M expected to fund operations into 2H 2025.","Phase 3 SAPPHIRE trial (apitegromab in SMA) topline data on track for 4Q 2024; potential launch 2025 if approved.","FDA cleared IND for Phase 2 obesity trial of apitegromab + GLP-1 RA; start mid-2024, data mid-2025.","Appointed Katie Peng to board; promoted Mo Qatanani to CSO in Feb 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035865","json":"https://secwatch.observer/filing/0001104659-24-035865.json","markdown":"https://secwatch.observer/filing/0001104659-24-035865.md","text":"https://secwatch.observer/filing/0001104659-24-035865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/0001104659-24-035865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/tm249126d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:34:07.404439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2177f356a94d998702c1e36d5f765731f2f5f738","claim":"Scholar Rock Holding Corp reported the full year ended December 31, 2023 results: net income $165.8 million or $1.99 per share, EPS $1.99 per share.","evidence_excerpt":"Full Year 2023 Financial Results For the full year ended December 31, 2023, net loss was $165.8 million or $1.99 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/0001104659-24-035865-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"$165.8 million or $1.99 per share"},{"label":"EPS","value":"$1.99 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}